Taysha Gene Therapies, Inc.TSHANASDAQ

Revenue (LTM)

$10M

+17.3% YoY

Net Income (LTM)

$-109M

-22.1% YoY

Free Cash Flow

$-94M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	0	3	15↑517.5%	8↓46.1%	10↑17.3%
Gross Profit	0	0	15↑102913.5%	8↓46.1%	0
Operating Income	-173	-126↑27.3%	-72↑42.5%	-91↓26.3%	-110↓20.8%
Net Income	-175	-166↑4.9%	-112↑32.8%	-89↑20.0%	-109↓22.1%
EBITDA	-173	-160↑7.5%	-105↑34.1%	-88↑16.4%	-110↓25.6%
EPS Diluted	-4.64	-3.78↑18.5%	-0.96↑74.6%	-0.36↑62.5%	-0.34↑5.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	149	88↓41.1%	144↑63.8%	139↓3.4%	320↑130.0%
Total Current Assets	160	96↓39.6%	150↑55.4%	142↓5.2%	325↑128.4%
Total Assets	214	126↓41.0%	173↑36.8%	160↓7.2%	343↑114.1%
Total Current Liabilities	52	63↑21.3%	37↓41.5%	26↓28.6%	27↑1.2%
Total Liabilities	119	125↑5.7%	98↓22.0%	89↓9.2%	96↑8.5%
Total Equity	95	1↓99.0%	75↑7796.4%	72↓4.6%	247↑245.2%
Total Debt	63	60↓5.0%	61↑2.0%	63↑3.4%	18↓71.2%
Net Debt	-86	-28↑67.5%	-83↓196.3%	-76↑8.4%	-302↓297.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-117	-88↑24.5%	-73↑17.4%	-81↓11.2%	-93↓14.6%
Capital Expenditure	-22	-25↓15.4%	-7↑70.4%	-0↑94.9%	-1↓97.3%
Free Cash Flow	-139	-113↑18.3%	-80↑29.0%	-82↓1.5%	-94↓15.0%
Stock-Based Comp	18	18↓0.8%	8↓56.2%	13↑65.8%	13↑1.5%
Net Change in Cash	-100	-61↑38.5%	56↑191.5%	-5↓108.8%	181↑3788.7%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance